Details

Autor(en) / Beteiligte

• Mathiesen, Jes Sloth
• Kroustrup, Jens Peter
• Vestergaard, Peter
• Stochholm, Kirstine
• Poulsen, Per Løgstrup
• Rasmussen, Åse Krogh
• Feldt-Rasmussen, Ulla
• Schytte, Sten
• Pedersen, Henrik Baymler
• Hahn, Christoffer Holst
• Bentzen, Jens
• Möller, Sören
• Gaustadnes, Mette
• Rossing, Maria
• Nielsen, Finn Cilius
• Brixen, Kim
• Frederiksen, Anja Lisbeth
• Godballe, Christian

Titel

Incidence and prevalence of multiple endocrine neoplasia 2A in Denmark 1901-2014: a nationwide study

Ist Teil von

• Clinical epidemiology, 2018-01, Vol.10, p.1479-1487

Ort / Verlag

New Zealand: Dove Medical Press Limited

Erscheinungsjahr

2018

Link zum Volltext

Quelle

Taylor & Francis Journals Auto-Holdings Collection

Beschreibungen/Notizen

• The incidence and prevalence of multiple endocrine neoplasia 2A (MEN2A) have only been reported once in a nationwide setting. However, it is unclear whether the figures are representative of other populations, as the major component of the syndrome, hereditary medullary thyroid carcinoma (MTC), has been reported as rare in the same country. We conducted a nationwide retrospective cohort study of MEN2A in Denmark from 1901 to 2014, aiming to describe the incidence and prevalence. This study included 250 unique MEN2A patients born or resident in Denmark before December 31, 2014. Patients were identified through the Danish arranged during ransfection ( ) cohort, linkage of MEN2A pedigrees, the Danish MTC cohort, a nationwide collaboration of MEN2 centers, cross-checking of other relevant cohorts, and a systematic literature search. The incidence from 1971 to 2000 was 28 (95% CI: 21-37) per million live births per year. Incidence for the specific mutations or for the overall MEN2A group did not change significantly from 1901 to 2014 ( >0.05). Point prevalence at January 1, 2015, was 24 per million (95% CI: 20-28). The incidence and prevalence of MEN2A in Denmark seem higher than those reported in other countries. This is likely explained by the Danish C611Y founder effect. Also, our data indicate no significant change in MEN2A incidence during the last century.